Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASCENT; ASCENT COPD
- Sponsors Actavis; AstraZeneca; Forest Laboratories
Most Recent Events
- 21 Oct 2020 Results of post-hoc analysis assessing efficacy and CV safety of AB in patients with and without chronic bronchitis, presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians.
- 21 Oct 2020 Results of post hoc analysis investigating factors associated with treatment response at 1 year in patients with more than 1 moderate/severe exacerbations in the prior year presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
- 21 Oct 2019 According to a Circassia media release, results have been presented at Respiratory Educational Reception at the American College of Chest Physicians CHEST Annual Meeting 2019.